Betting on allosteric mutations driving cancer, Black Diamond raises $85M in fresh round
Nearly a month after emerging from “stealth mode,” David Epstein-led cancer upstart Black Diamond Therapeutics said it has raised $85 million in a Series B round, bringing the funds raised by the first company out of Versant’s Ridgeline discovery engine in Basel to $105 million.
Oncogenes — which have the potential to cause the growth of cancer cells — are activated by kinase domain mutations or by allosteric mutations. Allostery is a common process by which proteins transmit the effect of binding at one site to another, often distal, functional site, allowing for regulation of activity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.